Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer

The heterogeneity of an individual patient's tumor has been linked to treatment resistance, but quantitative biomarkers to rapidly and reproducibly evaluate heterogeneity in a clinical setting are currently lacking. Using established tools available in a College of American Pathologists-accredi...

Full description

Saved in:

Bibliographic Details
Published in:	Cancer research (Chicago, Ill.) Vol. 77; no. 20; pp. 5687 - 5698
Main Authors:	Scher, Howard I, Graf, Ryon P, Schreiber, Nicole A, McLaughlin, Brigit, Jendrisak, Adam, Wang, Yipeng, Lee, Jerry, Greene, Stephanie, Krupa, Rachel, Lu, David, Bamford, Pascal, Louw, Jessica E, Dugan, Lyndsey, Vargas, Hebert A, Fleisher, Martin, Landers, Mark, Heller, Glenn, Dittamore, Ryan
Format:	Journal Article
Language:	English
Published:	United States American Association for Cancer Research, Inc 15-10-2017
Subjects:	Aged Aged, 80 and over Androgen receptors Androgens Cancer therapies Castration Chemotherapy Heterogeneity Humans Inhibitors Laboratories Male Metastases Metastasis Middle Aged Neoplasm Metastasis Neoplastic Cells, Circulating - drug effects Neoplastic Cells, Circulating - metabolism Neoplastic Cells, Circulating - pathology Pathology Patients Phenotype Prostate cancer Prostatic Neoplasms, Castration-Resistant - blood Prostatic Neoplasms, Castration-Resistant - drug therapy Prostatic Neoplasms, Castration-Resistant - pathology Receptors, Androgen - metabolism Retrospective Studies Taxanes Taxoids - pharmacology Tumor cells
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	The heterogeneity of an individual patient's tumor has been linked to treatment resistance, but quantitative biomarkers to rapidly and reproducibly evaluate heterogeneity in a clinical setting are currently lacking. Using established tools available in a College of American Pathologists-accredited and Clinical Laboratory Improvement Amendments-certified clinical laboratory, we quantified digital pathology features on 9,225 individual circulating tumor cells (CTC) from 179 unique metastatic castration-resistant prostate cancer (mCRPC) patients to define phenotypically distinct cell types. Heterogeneity was quantified on the basis of the diversity of cell types in individual patient samples using the Shannon index and associated with overall survival (OS) in the 145 specimens collected prior to initiation of the second or later lines of therapy. Low CTC phenotypic heterogeneity was associated with better OS in patients treated with androgen receptor signaling inhibitors (ARSI), whereas high heterogeneity was associated with better OS in patients treated with taxane chemotherapy. Overall, the results show that quantifying CTC phenotypic heterogeneity can help inform the choice between ARSI and taxanes in mCRPC patients. .
Bibliography:	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ISSN:	0008-5472 1538-7445
DOI:	10.1158/0008-5472.CAN-17-1353